NEURIZON THERAPEUTICS LIMITED (NUZ)
Share Price Analysis and Chart

21/08/2025

1

Speculative Buy

$0.42

162.50%

Morgans continues to view Neurizon Therapeutics as offering a robust proposition in the rare disease space. Clinical risks remain, but the analyst believes Nuz_001 is a drug based on a sound scientific basis with a robust safety profile.

The company announced its Ph1 OLE results, with Nuz_001 well tolerated over 2.5 years and showing a survival benefit of circa 16 months versus Pro_Act controls.

The results showed the decline from motor neuron disease (ALSFRS-R) slowed by -31%, with a respiratory decline of -43% and stable biomarkers.

The data were positive but mostly known by the market due to frequent updates. Speculative Buy. Target unchanged at 42c.

FORECAST
Morgans forecasts a full year FY25 dividend of 0.00 cents and EPS of 0.00 cents.
Morgans forecasts a full year FY26 dividend of 0.00 cents and EPS of 0.00 cents.

21/08/2025

1

Buy

$0.50

212.50%

Petra Capital notes the final data from NUZ-001 OLE study results for Amyotrophic Lateral Sclerosis (ALS) showed it is safe and well tolerated, and reduces risk of death by 76.7%.

The broker highlights there is strong preliminary evidence for the drug to be a disease-modifying therapy for ALS, supporting advancement into the pivotal HEALEY ALS platform trial.

A key overhang on the stock is the clinical hold by the FDA, and the broker expects removal on Oct 3.

Buy. Target unchanged at 50c.

FORECAST
Petra Capital forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -3.60 cents.
Petra Capital forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -3.40 cents.